XTX Topco Ltd boosted its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 129.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,219 shares of the company’s stock after purchasing an additional 13,103 shares during the period. Zoetis accounts for 0.3% of XTX Topco Ltd’s investment portfolio, making the stock its 18th biggest holding. XTX Topco Ltd’s holdings in Zoetis were worth $4,025,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in ZTS. Aveo Capital Partners LLC purchased a new position in Zoetis during the 4th quarter valued at about $225,000. Gryphon Financial Partners LLC boosted its holdings in shares of Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares during the period. Jump Financial LLC purchased a new position in Zoetis during the fourth quarter valued at approximately $339,000. Level Four Advisory Services LLC lifted its position in Zoetis by 11.7% in the 4th quarter. Level Four Advisory Services LLC now owns 1,504 shares of the company’s stock worth $297,000 after buying an additional 157 shares in the last quarter. Finally, TrinityPoint Wealth LLC boosted its stake in shares of Zoetis by 0.3% during the 4th quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock valued at $4,405,000 after buying an additional 73 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Up 0.4 %
Shares of ZTS stock opened at $196.48 on Thursday. The company has a market capitalization of $89.65 billion, a price-to-earnings ratio of 37.86, a PEG ratio of 2.98 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock’s 50 day simple moving average is $184.11 and its 200 day simple moving average is $174.31. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.
Analyst Ratings Changes
ZTS has been the topic of a number of research reports. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $218.22.
Get Our Latest Stock Report on ZTS
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- Trading Halts Explained
- Leverage Proven Stock Factors With These Top 3 Smart Beta ETFs
- Stock Sentiment Analysis: How it Works
- Spread Your Bets: Winning the AI Race With Energy ETFs
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Intuitive Machines Soars: NASA Contract Fuels Lunar Ambitions
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.